Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease.

Abstract	Phosphodiesterase-4 inhibitors (PDE4Is) are potent anti-inf lammatory agents and roflumilast has been used to prevent acute exacerbation of chronic obstructive pulmonary disease (COPD). Roflumilast decreases neutrophil migration, restores cystic fibrosis transmembrane conductance regulator activity, and recovers glucocorticoid effects. A forced expiratory volume in 1 second of < 50%, a chronic bronchitis phenotype, high blood eosinophil levels, and a history of hospitalization are biomarkers for predicting responses to roflumilast. Adverse effects are common in clinical practice. An inhaled PDE4I has recently been developed and is under clinical trial. CHF6001 and RPL554 exhibit promise and may be future treatment options for COPD.
Authors	Chin Kook Rhee, Deog Kyeom Kim
Journal	The Korean journal of internal medicine (Korean J Intern Med) Vol. 35 Issue 2 Pg. 276-283 (03 2020) ISSN: 2005-6648 [Electronic] Korea (South)
PMID	32131571 (Publication Type: Journal Article, Review)
Chemical References	Phosphodiesterase 4 Inhibitors Cyclic Nucleotide Phosphodiesterases, Type 4
Topics	Cyclic Nucleotide Phosphodiesterases, Type 4 Forced Expiratory Volume Humans Phosphodiesterase 4 Inhibitors (adverse effects) Pulmonary Disease, Chronic Obstructive (diagnosis, drug therapy) Respiratory Function Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!